BioCentury This Week
BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
All episodes
Best episodes
Seasons
Top 10 BioCentury This Week Episodes
Goodpods has curated a list of the 10 best BioCentury This Week episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to BioCentury This Week for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite BioCentury This Week episode by adding your comments to the episode page.
Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
BioCentury This Week
12/30/24 • 34 min
Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the legacy of Temple. Temple, who is retiring, crafted the modern clinical trial paradigm, created the accelerated approval pathway, and set precedents for incorporating patient perspectives in regulatory decisions. Usdin also discusses the opportunities and threats for the agency under Trump 2.0.BioCentury's editors also discuss China’s academic innovation, arguing that a wave of new target biology is now coming from Chinese university labs and the underwhelming results from CagriSema’s latest readout. Phase III data for the most important weight loss candidate from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) failed to differentiate the product from Eli Lilly's Zepbound.
View full story:https://www.biocentury.com/article/654574/temple-s-fda-legacy-plus-chinese-innovation-novo-obesity-data-a-biocentury-podcast
00:00 - Introduction
02:03 - Bob Temple's Legacy
16:13 - China's Academic Innovation
26:20 - CagriSema Obesity Data
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Ep. 46 - Pipeline plays for BMS, Rigel; plus J&J's vaccine panel & access for Africa
BioCentury This Week
02/23/21 • 21 min
Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule
BioCentury This Week
11/24/20 • 21 min
Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data
BioCentury This Week
07/06/20 • 15 min
Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics
BioCentury This Week
05/19/20 • 18 min
Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights
BioCentury This Week
11/22/21 • 23 min
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
BioCentury This Week
12/03/24 • 27 min
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump’s pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry.
The BioCentury team then discusses its analysis of abstracts released ahead of the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlighting methods for applying dual or bispecific CAR T cell designs to solid tumors. And they also analyze FDA approvals of products by biotech companies, noting that current trends show biotechs shedding their reliance on pharma to get drugs across the finish line for approval.
View full story: https://www.biocentury.com/article/654363
00:00 - Introduction
01:08 - Trump's NIH Pick
12:13 - Multi-targeted CAR Ts
19:26 - Biotech FDA Approvals
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Ep. 95 - ASH's New Targets, Avistone & Washington Update
BioCentury This Week
12/14/21 • 19 min
Ep. 264 - Prepping for Trump & Alzheimer's Ethics
BioCentury This Week
11/12/24 • 29 min
Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond.
BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed the results of APOE4 genotype testing to Alzheimer’s trial participants and investigations by Chinese authorities into AstraZeneca China President Leon Wang and fellow AZ employees past and current, assessing what’s known about the allegations and whether the situation could affect other MNCs operating in the country.
View full story: https://www.biocentury.com/article/654157
00:00 - Introduction
01:01 - Prepping for Trump
09:41 - Alzheimer's Ethics
17:44 - AstraZeneca's Challenges in China
21:51 - Myths and Misperceptions
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Show more best episodes
Show more best episodes
FAQ
How many episodes does BioCentury This Week have?
BioCentury This Week currently has 280 episodes available.
What topics does BioCentury This Week cover?
The podcast is about Life Sciences, Biotech, Research, Investment, Podcasts, Science, Business and Pharmaceutical.
What is the most popular episode on BioCentury This Week?
The episode title 'Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans' is the most popular.
What is the average episode length on BioCentury This Week?
The average episode length on BioCentury This Week is 23 minutes.
How often are episodes of BioCentury This Week released?
Episodes of BioCentury This Week are typically released every 6 days, 23 hours.
When was the first episode of BioCentury This Week?
The first episode of BioCentury This Week was released on Apr 22, 2020.
Show more FAQ
Show more FAQ